AU2021350835A1 - Prime editing guide rnas, compositions thereof, and methods of using the same - Google Patents
Prime editing guide rnas, compositions thereof, and methods of using the same Download PDFInfo
- Publication number
- AU2021350835A1 AU2021350835A1 AU2021350835A AU2021350835A AU2021350835A1 AU 2021350835 A1 AU2021350835 A1 AU 2021350835A1 AU 2021350835 A AU2021350835 A AU 2021350835A AU 2021350835 A AU2021350835 A AU 2021350835A AU 2021350835 A1 AU2021350835 A1 AU 2021350835A1
- Authority
- AU
- Australia
- Prior art keywords
- pegrna
- nucleotides
- napdnabp
- dna
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063083067P | 2020-09-24 | 2020-09-24 | |
| US63/083,067 | 2020-09-24 | ||
| US202063091272P | 2020-10-13 | 2020-10-13 | |
| US63/091,272 | 2020-10-13 | ||
| US202163182633P | 2021-04-30 | 2021-04-30 | |
| US63/182,633 | 2021-04-30 | ||
| US202163231231P | 2021-08-09 | 2021-08-09 | |
| US63/231,231 | 2021-08-09 | ||
| PCT/US2021/052097 WO2022067130A2 (en) | 2020-09-24 | 2021-09-24 | Prime editing guide rnas, compositions thereof, and methods of using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2021350835A1 true AU2021350835A1 (en) | 2023-04-27 |
| AU2021350835A2 AU2021350835A2 (en) | 2023-04-27 |
Family
ID=78302966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021350835A Pending AU2021350835A1 (en) | 2020-09-24 | 2021-09-24 | Prime editing guide rnas, compositions thereof, and methods of using the same |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230357766A1 (https=) |
| EP (1) | EP4217490A2 (https=) |
| JP (1) | JP2023543803A (https=) |
| AU (1) | AU2021350835A1 (https=) |
| CA (1) | CA3193099A1 (https=) |
| WO (1) | WO2022067130A2 (https=) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| IL310721B2 (en) | 2015-10-23 | 2025-11-01 | Harvard College | Nucleobase editors and uses thereof |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| US12390514B2 (en) | 2017-03-09 | 2025-08-19 | President And Fellows Of Harvard College | Cancer vaccine |
| US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| WO2020191233A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| WO2020252455A1 (en) | 2019-06-13 | 2020-12-17 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| IL297761A (en) | 2020-05-08 | 2022-12-01 | Broad Inst Inc | Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence |
| CA3189601A1 (en) | 2020-07-24 | 2022-01-27 | The General Hospital Corporation | Enhanced virus-like particles and methods of use thereof for delivery to cells |
| EP4232583A1 (en) | 2020-10-21 | 2023-08-30 | Massachusetts Institute of Technology | Systems, methods, and compositions for site-specific genetic engineering using programmable addition via site-specific targeting elements (paste) |
| US20220145334A1 (en) * | 2020-11-06 | 2022-05-12 | Pairwise Plants Services, Inc. | Compositions and methods for rna-encoded dna-replacement of alleles |
| JP2024521811A (ja) | 2021-05-28 | 2024-06-04 | サナ バイオテクノロジー，インコーポレイテッド | 短縮型ヒヒ内在性レトロウイルス（ＢａＥＶ）エンベロープ糖タンパク質を含む脂質粒子、ならびに関連する方法及び使用 |
| EP4352215A1 (en) * | 2021-06-11 | 2024-04-17 | LifeEDIT Therapeutics, Inc. | Rna polymerase iii promoters and methods of use |
| US20240358761A1 (en) | 2021-08-11 | 2024-10-31 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
| JP2024535677A (ja) | 2021-08-11 | 2024-10-02 | サナ バイオテクノロジー，インコーポレイテッド | 即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞 |
| EP4384598A1 (en) | 2021-08-11 | 2024-06-19 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
| AU2022325232A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified primary cells for allogeneic cell therapy |
| US20250313861A1 (en) | 2021-10-22 | 2025-10-09 | Sana Biotechnology, Inc. | Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods |
| WO2023115041A1 (en) | 2021-12-17 | 2023-06-22 | Sana Biotechnology, Inc. | Modified paramyxoviridae attachment glycoproteins |
| US20250059239A1 (en) | 2021-12-17 | 2025-02-20 | Sana Biotechnology, Inc. | Modified paramyxoviridae fusion glycoproteins |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| EP4472646A1 (en) | 2022-02-01 | 2024-12-11 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| EP4479416A1 (en) | 2022-02-17 | 2024-12-25 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
| EP4504921A4 (en) * | 2022-04-01 | 2026-04-15 | Prime Medicine Inc | METHODS AND COMPOSITIONS FOR EDITING NUCLEOTID SEQUENCES |
| EP4511488A2 (en) * | 2022-04-20 | 2025-02-26 | Tacit Therapeutics, Inc. | Stabilization of therapeutic trans-splicing rna molecules in human cells |
| WO2023215831A1 (en) * | 2022-05-04 | 2023-11-09 | Tome Biosciences, Inc. | Guide rna compositions for programmable gene insertion |
| US20250283112A1 (en) * | 2022-05-13 | 2025-09-11 | The Regents Of The University Of California | Compositions and Methods for RNA Editing |
| EP4534675A1 (en) * | 2022-05-25 | 2025-04-09 | Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences | Method for site-specific insertion of exogenous sequence in genome |
| US20250354177A1 (en) * | 2022-05-30 | 2025-11-20 | Wuhan University | System and methods for duplicating target fragments |
| CN114958767B (zh) * | 2022-06-02 | 2022-12-27 | 健颐生物科技发展(山东)有限公司 | 基于hiPSC细胞构建的神经干细胞制剂的制备方法 |
| EP4532702A1 (en) * | 2022-06-02 | 2025-04-09 | University of Massachusetts | High fidelity nucleotide polymerase chimeric prime editor systems |
| CN115948461A (zh) * | 2022-07-14 | 2023-04-11 | 五邑大学 | 一种双向导碱基基因编辑系统及其应用 |
| WO2024026344A1 (en) * | 2022-07-27 | 2024-02-01 | Inscripta, Inc. | Modulating cellular repair mechanisms for genomic editing |
| CN116064517A (zh) * | 2022-07-29 | 2023-05-05 | 之江实验室 | 一种先导编辑gRNA的产生方式及其用途 |
| US20260055146A1 (en) | 2022-08-24 | 2026-02-26 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| CN115948449B (zh) * | 2022-09-20 | 2026-03-27 | 浙江大学杭州国际科创中心 | 一种适用于酵母先导编辑的双质粒系统及应用 |
| EP4590819A2 (en) * | 2022-09-20 | 2025-07-30 | The Board of Trustees of the Leland Stanford Junior University | Methods and compositions to control gene using genome editing |
| WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| WO2024077267A1 (en) | 2022-10-07 | 2024-04-11 | The Broad Institute, Inc. | Prime editing methods and compositions for treating triplet repeat disorders |
| WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| WO2024086586A2 (en) * | 2022-10-18 | 2024-04-25 | Flagship Pioneering Innovations Vi, Llc | Improved gene editing systems utilizing trans recruiting components |
| WO2024097313A1 (en) | 2022-11-02 | 2024-05-10 | Sana Biotechnology, Inc. | Methods for producing t cell therapy products |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| WO2024151541A1 (en) | 2023-01-09 | 2024-07-18 | Sana Biotechnology, Inc. | Type-1 diabetes autoimmune mouse |
| WO2024168116A1 (en) | 2023-02-08 | 2024-08-15 | Prime Medicine, Inc. | Genome editing compositions and methods for treatment of myotonic dystrophy |
| WO2024168147A2 (en) | 2023-02-09 | 2024-08-15 | The Broad Institute, Inc. | Evolved recombinases for editing a genome in combination with prime editing |
| WO2024170866A1 (en) * | 2023-02-16 | 2024-08-22 | Genome Research Limited | Methods for modifying a cell genome |
| WO2024206125A1 (en) * | 2023-03-24 | 2024-10-03 | The Broad Institute, Inc. | Use of prime editing for treating sickle cell disease |
| WO2024215712A2 (en) * | 2023-04-11 | 2024-10-17 | University Of Washington | Methods for identifying epigenetic factors influencing gene editing and modulating gene editing outcome via epigenetic modulation |
| WO2024220135A1 (en) | 2023-04-17 | 2024-10-24 | University Of Massachusetts | Prime editing systems having pegrna with reduced auto-inhibitory interaction |
| EP4698666A1 (en) | 2023-04-18 | 2026-02-25 | Sana Biotechnology, Inc. | Universal protein g fusogens and adapter systems thereof and related lipid particles and uses |
| WO2024220560A1 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Engineered protein g fusogens and related lipid particles and methods thereof |
| WO2024220598A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Lentiviral vectors with two or more genomes |
| AU2024264889A1 (en) | 2023-05-03 | 2025-11-13 | Sana Biotechnology, Inc. | Methods of dosing and administration of engineered islet cells |
| EP4716541A2 (en) | 2023-05-22 | 2026-04-01 | Sana Biotechnology, Inc. | Methods of delivery of islet cells and related methods |
| WO2024243415A1 (en) | 2023-05-23 | 2024-11-28 | The Broad Institute, Inc. | Evolved and engineered prime editors with improved editing efficiency |
| EP4716750A1 (en) | 2023-05-23 | 2026-04-01 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| AU2024301706A1 (en) | 2023-07-21 | 2026-02-05 | Crispr Therapeutics Ag | Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene |
| WO2025038881A1 (en) * | 2023-08-16 | 2025-02-20 | Beam Therapeutics Inc. | Prime editing of single base mutations in sickle cell disease |
| WO2025049563A1 (en) * | 2023-08-28 | 2025-03-06 | University Of Florida Research Foundation, Inc. | A programmable gene correction technology using cas-polymerase constructs |
| AU2024335327A1 (en) * | 2023-09-01 | 2026-03-26 | Renagade Therapeutics Management Inc. | Gene editing systems, compositions, and methods for treatment of vexas syndrome |
| WO2025054202A1 (en) | 2023-09-05 | 2025-03-13 | Sana Biotechnology, Inc. | Method of screening a sample comprising a transgene with a unique barcode |
| WO2025076306A1 (en) | 2023-10-06 | 2025-04-10 | University Of Massachusetts | Prime editors having improved prime editing efficiency |
| WO2025096936A2 (en) | 2023-11-03 | 2025-05-08 | The Broad Institute, Inc. | Use of prime editing in correcting mutations in cdkl5 |
| WO2025111452A2 (en) * | 2023-11-21 | 2025-05-30 | Prime Medicine, Inc. | CHEMICAL MODIFICATIONS IN PEgRNA and ngRNAs |
| KR20250075782A (ko) * | 2023-11-21 | 2025-05-29 | 경상국립대학교산학협력단 | 교정 정밀도가 향상된 프라임 에디팅 시스템 및 이의 용도 |
| CN117497092B (zh) * | 2024-01-02 | 2024-05-14 | 微观纪元(合肥)量子科技有限公司 | 基于动态规划和量子退火的rna结构预测方法及系统 |
| WO2025151814A1 (en) | 2024-01-10 | 2025-07-17 | The Broad Institute, Inc. | Use of prime editing in correcting mutations in cftr |
| WO2025151838A1 (en) | 2024-01-12 | 2025-07-17 | Sana Biotechnology, Inc. | Safety switches to control in vitro and in vivo proliferation of cell therapy products |
| EP4600357A1 (en) * | 2024-02-12 | 2025-08-13 | Technische Universität München | Delivery system for gene editing tools |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| WO2025188920A1 (en) | 2024-03-06 | 2025-09-12 | Mdx Management Llc | Local application of agents inhibiting tyrosine kinase or shp-1 signaling |
| WO2025212519A1 (en) | 2024-04-01 | 2025-10-09 | Moonlight Bio, Inc. | Dll3 binding proteins and uses thereof |
| US20250313863A1 (en) * | 2024-04-09 | 2025-10-09 | Trustees Of Boston University | ENGINEERED CIRCULARIZED pegRNAs AND USES THEREOF |
| WO2025217616A1 (en) | 2024-04-12 | 2025-10-16 | The Broad Institute, Inc. | Prime editing and base editing of the atp1a3 gene for the treatment of alternating hemiplegia of childhood |
| WO2025235828A2 (en) * | 2024-05-08 | 2025-11-13 | The General Hospital Corporation | Engineered prime editors for treating genetic deafness |
| WO2025240795A1 (en) * | 2024-05-15 | 2025-11-20 | President And Fellows Of Harvard College | End-modified grnas for improved base editing |
| WO2025250677A1 (en) * | 2024-05-28 | 2025-12-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for correction of trex1 mutations |
| CN118581153A (zh) * | 2024-08-05 | 2024-09-03 | 崖州湾国家实验室 | Dna聚合酶介导的核苷酸序列编辑方法及组合物 |
| WO2026069163A1 (en) | 2024-09-25 | 2026-04-02 | Crispr Therapeutics Ag | Differentiation method for producing immature beta cells |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663290A (en) | 1982-01-21 | 1987-05-05 | Molecular Genetics, Inc. | Production of reverse transcriptase |
| US4889818A (en) | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
| US5079352A (en) | 1986-08-22 | 1992-01-07 | Cetus Corporation | Purified thermostable enzyme |
| US5374553A (en) | 1986-08-22 | 1994-12-20 | Hoffmann-La Roche Inc. | DNA encoding a thermostable nucleic acid polymerase enzyme from thermotoga maritima |
| US5244797B1 (en) | 1988-01-13 | 1998-08-25 | Life Technologies Inc | Cloned genes encoding reverse transcriptase lacking rnase h activity |
| FR2632821B1 (fr) | 1988-06-22 | 1990-11-16 | Inst Kriobiologii | Procede de conservation a basse temperature des embryons |
| US5270179A (en) | 1989-08-10 | 1993-12-14 | Life Technologies, Inc. | Cloning and expression of T5 DNA polymerase reduced in 3'- to-5' exonuclease activity |
| US5047342A (en) | 1989-08-10 | 1991-09-10 | Life Technologies, Inc. | Cloning and expression of T5 DNA polymerase |
| JP2709311B2 (ja) | 1990-09-28 | 1998-02-04 | エフ．ホフマン−ラ ロシュ アクチェンゲゼルシャフト | 熱安定性ｄｎａポリメラーゼの５→３′のエキソヌクレアーゼ突然変異 |
| AU8906091A (en) | 1990-10-05 | 1992-04-28 | Wayne M. Barnes | Thermostable dna polymerase |
| US5496714A (en) | 1992-12-09 | 1996-03-05 | New England Biolabs, Inc. | Modification of protein by use of a controllable interveining protein sequence |
| US5834247A (en) | 1992-12-09 | 1998-11-10 | New England Biolabs, Inc. | Modified proteins comprising controllable intervening protein sequences or their elements methods of producing same and methods for purification of a target protein comprised by a modified protein |
| US5436149A (en) | 1993-02-19 | 1995-07-25 | Barnes; Wayne M. | Thermostable DNA polymerase with enhanced thermostability and enhanced length and efficiency of primer extension |
| US5512462A (en) | 1994-02-25 | 1996-04-30 | Hoffmann-La Roche Inc. | Methods and reagents for the polymerase chain reaction amplification of long DNA sequences |
| US5912155A (en) | 1994-09-30 | 1999-06-15 | Life Technologies, Inc. | Cloned DNA polymerases from Thermotoga neapolitana |
| US5614365A (en) | 1994-10-17 | 1997-03-25 | President & Fellow Of Harvard College | DNA polymerase having modified nucleotide binding site for DNA sequencing |
| US5773258A (en) | 1995-08-25 | 1998-06-30 | Roche Molecular Systems, Inc. | Nucleic acid amplification using a reversibly inactivated thermostable enzyme |
| US6183998B1 (en) | 1998-05-29 | 2001-02-06 | Qiagen Gmbh Max-Volmer-Strasse 4 | Method for reversible modification of thermostable enzymes |
| GB9920194D0 (en) | 1999-08-27 | 1999-10-27 | Advanced Biotech Ltd | A heat-stable thermostable DNA polymerase for use in nucleic acid amplification |
| EP1235914A2 (en) | 1999-11-24 | 2002-09-04 | Joseph Rosenecker | Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells |
| US8178291B2 (en) | 2005-02-18 | 2012-05-15 | Monogram Biosciences, Inc. | Methods and compositions for determining hypersusceptibility of HIV-1 to non-nucleoside reverse transcriptase inhibitors |
| US9783791B2 (en) | 2005-08-10 | 2017-10-10 | Agilent Technologies, Inc. | Mutant reverse transcriptase and methods of use |
| EP2139909A4 (en) * | 2007-03-22 | 2010-04-07 | Univ Yale Inc | PREQ1-RIBOSWITCHES AND METHOD AND COMPOSITIONS FOR USE BY AND WITH PREQ1-RIBOSWITCHES |
| CN101668848B (zh) | 2007-04-26 | 2014-10-22 | 雷蒙特亚特特拉维夫大学有限公司 | 来自口腔粘膜的多能自体干细胞和使用方法 |
| WO2010028347A2 (en) | 2008-09-05 | 2010-03-11 | President & Fellows Of Harvard College | Continuous directed evolution of proteins and nucleic acids |
| US10113156B2 (en) | 2009-03-04 | 2018-10-30 | Board Of Regents, The University Of Texas System | Stabilized reverse transcriptase fusion proteins |
| US8889394B2 (en) | 2009-09-07 | 2014-11-18 | Empire Technology Development Llc | Multiple domain proteins |
| WO2011072246A2 (en) | 2009-12-10 | 2011-06-16 | Regents Of The University Of Minnesota | Tal effector-mediated dna modification |
| WO2012054727A1 (en) | 2010-10-22 | 2012-04-26 | Bio-Rad Laboratories, Inc. | Reverse transcriptase mixtures with improved storage stability |
| CA2825370A1 (en) | 2010-12-22 | 2012-06-28 | President And Fellows Of Harvard College | Continuous directed evolution |
| WO2012125445A2 (en) | 2011-03-11 | 2012-09-20 | President And Fellows Of Harvard College | Small molecule-dependent inteins and uses thereof |
| KR102096534B1 (ko) | 2011-09-28 | 2020-04-03 | 에라 바이오테크, 에스.에이. | 분할된 인테인 및 그의 이용 |
| EP3431497B1 (en) | 2012-06-27 | 2022-07-27 | The Trustees of Princeton University | Split inteins, conjugates and uses thereof |
| US9181535B2 (en) | 2012-09-24 | 2015-11-10 | The Chinese University Of Hong Kong | Transcription activator-like effector nucleases (TALENs) |
| DK2904101T3 (da) | 2012-10-03 | 2019-08-12 | Agrivida Inc | Intein-modificerede proteaser, fremstilling deraf og industrielle anvendelser |
| JO3470B1 (ar) | 2012-10-08 | 2020-07-05 | Merck Sharp & Dohme | مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9228207B2 (en) * | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| WO2015134121A2 (en) | 2014-01-20 | 2015-09-11 | President And Fellows Of Harvard College | Negative selection and stringency modulation in continuous evolution systems |
| CN107075491B (zh) | 2014-10-28 | 2021-07-06 | 谷万达公司 | 用于稳定反式剪接的内含肽修饰的蛋白酶的方法和组合物 |
| WO2016168631A1 (en) | 2015-04-17 | 2016-10-20 | President And Fellows Of Harvard College | Vector-based mutagenesis system |
| ES2985812T3 (es) * | 2016-09-09 | 2024-11-07 | The Board Of Trustees Of The Leland Stanfordjunior Univ | Edición genómica de precisión de alto rendimiento |
| US9580698B1 (en) | 2016-09-23 | 2017-02-28 | New England Biolabs, Inc. | Mutant reverse transcriptase |
| US11560566B2 (en) * | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| US10011849B1 (en) * | 2017-06-23 | 2018-07-03 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| US11268092B2 (en) * | 2018-01-12 | 2022-03-08 | GenEdit, Inc. | Structure-engineered guide RNA |
| KR20250133482A (ko) * | 2018-05-11 | 2025-09-05 | 빔 테라퓨틱스, 인크. | 프로그래밍가능한 염기 편집기 시스템을 이용하여 단일 뉴클레오티드 다형성을 편집하는 방법 |
| WO2020191233A1 (en) * | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| IL297761A (en) * | 2020-05-08 | 2022-12-01 | Broad Inst Inc | Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence |
-
2021
- 2021-09-24 CA CA3193099A patent/CA3193099A1/en active Pending
- 2021-09-24 EP EP21795122.7A patent/EP4217490A2/en active Pending
- 2021-09-24 WO PCT/US2021/052097 patent/WO2022067130A2/en not_active Ceased
- 2021-09-24 JP JP2023519084A patent/JP2023543803A/ja active Pending
- 2021-09-24 AU AU2021350835A patent/AU2021350835A1/en active Pending
- 2021-09-24 US US18/028,183 patent/US20230357766A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022067130A2 (en) | 2022-03-31 |
| EP4217490A2 (en) | 2023-08-02 |
| US20230357766A1 (en) | 2023-11-09 |
| JP2023543803A (ja) | 2023-10-18 |
| AU2021350835A2 (en) | 2023-04-27 |
| WO2022067130A3 (en) | 2022-06-23 |
| CA3193099A1 (en) | 2022-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12031126B2 (en) | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence | |
| US20230357766A1 (en) | Prime editing guide rnas, compositions thereof, and methods of using the same | |
| US12509680B2 (en) | Methods and compositions for prime editing nucleotide sequences | |
| CN116685682A (zh) | 引导编辑向导rna、其组合物以及使用它们的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 MAR 2023 |